Key Clinical Summary: Implementing Outpatient and Hybrid of BCMA BsAbs

This is a micro-learning module summary of a presentation by Dr Joshua Richter which you can find here. Before participating, please read our CME and disclosure information which can be found here.

This activity is supported by an independent medical educational grant from Johnson & Johnson. This online education program has been designed for US Healthcare Professionals.

Transitioning the administration of B-cell maturation antigen (BCMA) bispecific antibodies (BsAbs) for relapsed/refractory multiple myeloma (RRMM) from inpatient to outpatient or hybrid models requires careful patient selection, specialized institutional infrastructure, and proactive toxicity management.

Patient Selection and Eligibility

Monitoring Capability: Patients must be cognitively intact and capable of using home monitoring devices, such as a blood pressure cuff, thermometer, and pulse oximeter, to regularly report vitals.
Caregiver Support: A dedicated care partner must be available 24/7 to continuously monitor the patient for 72 hours after each step-up dose (SUD) and assist with communication.
Logistics and Performance Status: Patients must have reliable internet access, reside or stay within 30 minutes to 1 hour of the administering facility during the high-risk window, and maintain a strong performance status (ECOG 0 or 1).
Risk Factors: Patients with high disease burden, significant comorbidities, or absent caregiver support are generally better suited for inpatient initiation.

Agent-Specific Considerations

Teclistamab and Elranatamab (Subcutaneous): The median onset for cytokine release syndrome (CRS) is approximately 2 days. Outpatient models require reliable caregiver observation and rapid return-to-care pathways during this delayed risk window.
Linvoseltamab (Intravenous): The median onset for CRS is much shorter, at approximately 10 to 11 hours. Intravenous administration carries a risk of infusion-related adverse events during the first 1 to 4 hours, demanding vigilant overnight surveillance.
Talquetamab (Subcutaneous, GPRC5D-targeted): The median CRS onset is approximately 27 hours. Providers must also proactively monitor and manage medium-term functional toxicities, including oral, taste, skin, and nail changes.

Prophylaxis Protocols

CRS Prevention: The administration of prophylactic tocilizumab (8 mg/kg) prior to the first step-up dose significantly reduces the onset and severity of CRS without diminishing BsAb efficacy. Because tocilizumab has a 2-week half-life, a single dose typically covers the patient throughout the entire step-up dosing process, reducing the need for recurrent hospital stays.
Infection Prevention: Patients must receive up-to-date vaccinations (influenza, COVID, RSV, pneumonia) prior to initiating therapy due to blunted immune responses on BCMA agents.
Standard Antimicrobial Prophylaxis: Regimens must include prophylaxis for herpes simplex virus (HSV), varicella-zoster virus (VZV), and Pneumocystis jirovecii pneumonia (PJP). Hepatitis B (HBV) prophylaxis is required for patients at risk of reactivation, but routine antifungal prophylaxis (e.g., fluconazole) is not necessary.
Primary IVIG Prophylaxis: Initiating primary prophylaxis with intravenous immune globulin (IVIG)—typically starting on Cycle 2 Day 1—is strongly recommended and has been shown to reduce the risk of grade 3 to 5 infections tenfold.

Adverse Event Management and Infrastructure

The "Pocket Dex" Strategy: Discharging patients with an oral prescription for dexamethasone (e.g., 10 mg) allows them to immediately self-administer treatment at home if early CRS symptoms, such as fever, occur during off-hours. This halts symptom escalation while the patient coordinates with the oncology team or travels to the hospital.
Multidisciplinary Infrastructure: Successful outpatient administration relies on robust standard operating procedures (SOPs), cross-departmental staff training (including emergency department and neurology staff), and a single 24/7 contact pathway to prevent off-hours communication breakdowns.

Content is accurate as of the date of release.